Pretreatment demographics
| . | Obinutuzumab 1000 mg (n = 41) . | Obinutuzumab 2000 mg (n = 39) . | All patients (n = 80) . |
|---|---|---|---|
| Median age, y (range) | 67 (37-87) | 65 (38-91) | 67 (34-91) |
| Female, n (%) | 16 (39) | 13 (33) | 29 (36) |
| Rai stage III/IV, n (%) | 16 (39) | 17 (43) | 33 (41) |
| Binet C, n (%) | 14 (34) | 14 (36) | 28 (35) |
| ECOG performance status, n (%) | |||
| 0 | 18 (45) | 22 (58) | 40 (51) |
| 1 | 21 (53) | 14 (37) | 35 (45) |
| 2 | 1 (3) | 2 (5) | 3 (4) |
| Median white blood cell count, 109/L (range) | 58.90 (8.0-350.2) | 77.85 (7.4-319.7) | 68.75 (7.4-350.2) |
| Median platelet count, 109/L (range) | 130.5 (14-300) | 144.5 (59-294) | 137.5 (14-300) |
| Median hemoglobin, g/dL (range) | 12 (8.2-15.1) | 12.2 (7.8-15.7) | 12.1 (7.8-15.7) |
| Splenomegaly, n (%) | 5 (18) | 4 (15) | 9 (17) |
| Cytogenetics, n (%) | n = 41 | n = 37 | n = 78 |
| 13q− | 12 (29) | 16 (43) | 28 (36) |
| Trisomy 12 | 7 (17) | 7 (19) | 14 (18) |
| 11q− | 7 (17) | 2 (5) | 9 (12) |
| 17p− | 4 (10) | 4 (11) | 8 (10) |
| No abnormality | 11 (27) | 8 (22) | 19 (24) |
| IGHV unmutated, n (%) | n = 38 | n = 38 | n = 76 |
| Mutated, n (%) | 11 (29) | 15 (40) | 26 (34) |
| Unmutated, n (%) | 22 (58) | 19 (50) | 41 (54) |
| Not done, n (%) | 5 (13) | 4 (10) | 9 (12) |
| CD38 expression ≥30%, n (%) | 25/35 (71) | 20/36 (56) | 45/71 (68) |
| β2-Microglobulin ≥3.5 mg/L, n (%) | 26/35 (74) | 15/25 (60) | 41/60 (68) |
| Serum thymidine kinase ≥140 DU/L, n (%) | 15/21 (71) | 13/21 (62) | 28/42 (67) |
| . | Obinutuzumab 1000 mg (n = 41) . | Obinutuzumab 2000 mg (n = 39) . | All patients (n = 80) . |
|---|---|---|---|
| Median age, y (range) | 67 (37-87) | 65 (38-91) | 67 (34-91) |
| Female, n (%) | 16 (39) | 13 (33) | 29 (36) |
| Rai stage III/IV, n (%) | 16 (39) | 17 (43) | 33 (41) |
| Binet C, n (%) | 14 (34) | 14 (36) | 28 (35) |
| ECOG performance status, n (%) | |||
| 0 | 18 (45) | 22 (58) | 40 (51) |
| 1 | 21 (53) | 14 (37) | 35 (45) |
| 2 | 1 (3) | 2 (5) | 3 (4) |
| Median white blood cell count, 109/L (range) | 58.90 (8.0-350.2) | 77.85 (7.4-319.7) | 68.75 (7.4-350.2) |
| Median platelet count, 109/L (range) | 130.5 (14-300) | 144.5 (59-294) | 137.5 (14-300) |
| Median hemoglobin, g/dL (range) | 12 (8.2-15.1) | 12.2 (7.8-15.7) | 12.1 (7.8-15.7) |
| Splenomegaly, n (%) | 5 (18) | 4 (15) | 9 (17) |
| Cytogenetics, n (%) | n = 41 | n = 37 | n = 78 |
| 13q− | 12 (29) | 16 (43) | 28 (36) |
| Trisomy 12 | 7 (17) | 7 (19) | 14 (18) |
| 11q− | 7 (17) | 2 (5) | 9 (12) |
| 17p− | 4 (10) | 4 (11) | 8 (10) |
| No abnormality | 11 (27) | 8 (22) | 19 (24) |
| IGHV unmutated, n (%) | n = 38 | n = 38 | n = 76 |
| Mutated, n (%) | 11 (29) | 15 (40) | 26 (34) |
| Unmutated, n (%) | 22 (58) | 19 (50) | 41 (54) |
| Not done, n (%) | 5 (13) | 4 (10) | 9 (12) |
| CD38 expression ≥30%, n (%) | 25/35 (71) | 20/36 (56) | 45/71 (68) |
| β2-Microglobulin ≥3.5 mg/L, n (%) | 26/35 (74) | 15/25 (60) | 41/60 (68) |
| Serum thymidine kinase ≥140 DU/L, n (%) | 15/21 (71) | 13/21 (62) | 28/42 (67) |
ECOG, Eastern Cooperative Oncology Group.